Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

Giuseppe Cabibbo, Rodolfo Sacco, Massimo De Giorgio, Emanuela Rolle, Tiziana Pressiani, Francesca Spada

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.
    Original languageEnglish
    Pages (from-to)1807-1816
    Number of pages10
    JournalExpert Review of Anticancer Therapy
    Volume11
    Publication statusPublished - 2011

    Fingerprint

    Hepatocellular Carcinoma
    Gastroenterology
    Protein-Tyrosine Kinases
    Liver Diseases
    Therapeutics
    Safety
    Survival
    sorafenib
    Liver
    Pharmaceutical Preparations

    All Science Journal Classification (ASJC) codes

    • Oncology
    • Pharmacology (medical)

    Cite this

    Cabibbo, G., Sacco, R., De Giorgio, M., Rolle, E., Pressiani, T., & Spada, F. (2011). Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Review of Anticancer Therapy, 11, 1807-1816.

    Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. / Cabibbo, Giuseppe; Sacco, Rodolfo; De Giorgio, Massimo; Rolle, Emanuela; Pressiani, Tiziana; Spada, Francesca.

    In: Expert Review of Anticancer Therapy, Vol. 11, 2011, p. 1807-1816.

    Research output: Contribution to journalArticle

    Cabibbo, G, Sacco, R, De Giorgio, M, Rolle, E, Pressiani, T & Spada, F 2011, 'Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.', Expert Review of Anticancer Therapy, vol. 11, pp. 1807-1816.
    Cabibbo, Giuseppe ; Sacco, Rodolfo ; De Giorgio, Massimo ; Rolle, Emanuela ; Pressiani, Tiziana ; Spada, Francesca. / Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11. pp. 1807-1816.
    @article{ed7e2653a53d45549105624e6d188ef2,
    title = "Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.",
    abstract = "Sorafenib (Nexavar{\circledR}, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.",
    keywords = "hepatocellular carcinoma, sorafenb, cirrhosis",
    author = "Giuseppe Cabibbo and Rodolfo Sacco and {De Giorgio}, Massimo and Emanuela Rolle and Tiziana Pressiani and Francesca Spada",
    year = "2011",
    language = "English",
    volume = "11",
    pages = "1807--1816",
    journal = "Expert Review of Anticancer Therapy",
    issn = "1473-7140",
    publisher = "Expert Reviews Ltd.",

    }

    TY - JOUR

    T1 - Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.

    AU - Cabibbo, Giuseppe

    AU - Sacco, Rodolfo

    AU - De Giorgio, Massimo

    AU - Rolle, Emanuela

    AU - Pressiani, Tiziana

    AU - Spada, Francesca

    PY - 2011

    Y1 - 2011

    N2 - Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.

    AB - Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.

    KW - hepatocellular carcinoma, sorafenb, cirrhosis

    UR - http://hdl.handle.net/10447/64591

    M3 - Article

    VL - 11

    SP - 1807

    EP - 1816

    JO - Expert Review of Anticancer Therapy

    JF - Expert Review of Anticancer Therapy

    SN - 1473-7140

    ER -